Visfatin, a novel adipokine with insulinmimetic characteristics, is highly expressed in visceral fat.
1 Associations of circulating visfatin concentrations with diabetes and obesity have not been rigorously established, most likely due to small sample sizes of prior studies. Furthermore, relations of visfatin to other cardiovascular risk factors in the general population have not been examined systematically. Accordingly, we tested the hypothesis that plasma visfatin would be positively related to obesity, diabetes and visceral adiposity in a community-based sample.
Research Design and Methods
The design and selection criteria of the Framingham Third Generation Cohort (Gen 3) are detailed elsewhere.
2 Briefly, 4095 adults (53% women; mean age, 40 years) having at least one parent in the Framingham Offspring Study cohort were recruited in [2001] [2002] [2003] [2004] [2005] . At their first examination, participants underwent anthropometry, medical history and physical examination, laboratory assessment of cardiovascular risk factors, and, in a subsample, imaging for coronary calcification and adiposity using multi-detector computer tomography (MDCT). The present study was performed in a subsample of 374 participants (9% of eligible; 53% women) in whom plasma visfatin was assayed. We randomly selected these participants using a weighted sampling scheme with oversampling of the lowest and highest sexspecific quintiles of body mass index (BMI; ratio of 1.5:2:1.5 for the lowest, middle three and upper quintiles), using the participants undergoing MDCT imaging as the sampling frame. We chose this sampling strategy for costefficiency and for optimizing use of nonrenewable serological resources (given the novelty of the biomarker), keeping in mind that prior studies reported both direct 3-9 and inverse [10] [11] [12] relations of plasma visfatin to adiposity and diabetes. Visfatin was assayed using a commercially-available ELISA kit (Phoenix Pharmaceuticals Inc, Belmont, CA; interassay coefficient of variation, 4.9%) in plasma samples drawn after an overnight fast, and stored at -70°C. Subcutaneous and visceral adipose tissue volumes were measured using an eightslice MDCT scan of the abdomen (Aquarius 3D Workstation, TeraRecon Inc., San Mateo, CA) consisting of 50 five-mm thick slices covering 150 mm above the upper edge of S1. Briefly, abdominal adipose tissue was identified semi-automatically based on a threshold algorithm using the non-overlapping CT attenuations of fatty tissue, muscle, and air as differentiators.
13
Covariates and the metabolic syndrome 14 were defined as in Table 1 .
Visfatin concentrations were logarithmically-transformed to normalize the skewed distribution. Ageand sex-adjusted Spearman partial correlation coefficients were calculated to relate visfatin to cardiovascular risk factors. Due to reports of low and high visfatin levels in diabetes and obesity, we compared the adjusted-prevalences of cardiovascular risk factors (modeled as binary variables, defined above) in the lowest and in the uppermost quintile of visfatin with their prevalence in the middle-three quintiles (referent) using chi-square tests. A two-sided p<0.05 was considered statistically significant.
Results
Clinical characteristics of our sample and correlations of plasma visfatin with cardiovascular risk factors are shown in the Table. Borderline statistically significant correlations were observed between plasma visfatin and age (positive), and triglycerides (inverse correlation). Visfatin levels were not significantly related to any of the other clinical characteristics or with MDCTdetermined visceral or subcutaneous fat. Clinical variables explained less than 2% (model R 2 ) of the interindividual variation in visfatin concentrations. Modeling risk factors as categorical variables, we observed an association between prevalence of hypertension and visfatin (p=0.042). The prevalence of hypertension was lower in both the lowest (18%) and highest (15%) visfatin quintiles compared to that in the referent middle three quintiles (27%). Plasma visfatin was not significantly associated with dyslipidemia, obesity (generalized or abdominal) or diabetes (Table) . With our sample size, we had 80% power to detect an increment to the model R 2 of 0.024, and to observe a partial correlation coefficient of 0.16 or greater (at alpha=0.05). Also, studies relating plasma visfatin to insulin sensitivity or glucose tolerance have reported both direct 1 and no associations. 7, 8, 11, 12 . A recent investigation noted a positive relation of plasma visfatin to acute insulin response to intravenous glucose load, but not to metabolic risk factors or insulin sensitivity. 5 Further, these conflicting findings on correlates of plasma visfatin extend also to reports comparing visfatin expression in visceral versus subcutaneous adipose tissue; higher 1 and similar 8 levels have been observed in visceral compared to subcutaneous fat. In the present study, we did not find statistically significant associations between plasma visfatin and diabetes, obesity (generalized or abdominal; subcutaneous or visceral fat), or dyslipidemia. The biological relevance of the inverted U-shaped relation of visfatin and hypertension we observed is unclear, and it might represent a false positive finding. Potential explanations of our negative findings include that ours was a community-based cohort study, whereas prior investigations were smaller casecontrol studies of patients with diabetes or obesity, [3] [4] [5] [6] [7] [9] [10] [11] [12] or based on patients referred to hospital for abdominal surgery.
Conclusions
8 Notably, only six percent of participants in our sample had diabetes, which might have limited our power to detect an association. Further, the lack of association of plasma visfatin with cardiovascular risk factors does not negate an important physiological role for this novel adipokine. There were several limitations of our study. First, we had limited statistical power to detect modest associations given that our study is based on a subsample (9%) of the whole cohort and had a low prevalence of diabetes (6%). Second, plasma visfatin concentrations may not adequately reflect tissue activity. Third, we did not relate plasma visfatin to measures of insulin sensitivity/secretion. Overall, our findings, based on investigation of a moderate-size community-based sample, suggest that circulating visfatin may not be a useful clinical biomarker of metabolic traits. Fourth, our sample consisted of middleaged, white individuals, limiting the generalizability of our findings to other ages and ethnicities. Fifth, since our study was cross-sectional, we cannot assess if visfatin levels are related to longitudinal tracking of metabolic traits. 
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